Drug guidance
Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma
Condition
Blood and Immune System
Cancer
17 February 2025
Published on 13 Sep 2024
Last Updated on 4 Jun 2025
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Axicabtagene ciloleucel suspension for intravenous infusion for treating patients 18 years of age and above with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy, and who are intended for transplant.
Funding status
Axicabtagene ciloleucel suspension for intravenous infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 April 2025.
Axicabtagene ciloleucel should be used in line with the additional clinical criteria listed in the Annex.